{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T17:24:53Z","timestamp":1787246693950,"version":"build-2736575974"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T00:00:00Z","timestamp":1782086400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T00:00:00Z","timestamp":1782086400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100022606","name":"Almirall","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100022606","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1007\/s13555-026-01829-4","type":"journal-article","created":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T13:30:31Z","timestamp":1782135031000},"page":"4067-4082","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Duration-Dependent Adverse Events of Systemic Glucocorticosteroids in Atopic Dermatitis: A Nationwide Claims Cohort Study"],"prefix":"10.1007","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-0760-3103","authenticated-orcid":false,"given":"Theresa","family":"Klinger","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-5797-4014","authenticated-orcid":false,"given":"Katharina","family":"M\u00fcller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0149-479X","authenticated-orcid":false,"given":"Ricarda","family":"Graf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4026-8728","authenticated-orcid":false,"given":"Matthias","family":"Augustin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2676-1479","authenticated-orcid":false,"given":"Kristina","family":"Hagenstr\u00f6m","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,22]]},"reference":[{"key":"1829_CR1","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1007\/s40257-015-0171-3","volume":"17","author":"C Blome","year":"2016","unstructured":"Blome C, Radtke AM, Eissing L, Augustin M. Quality of life in patients with atopic dermatitis: disease burden, measurement, and treatment benefit. Am J Clin Dermatol. 2016;17:163\u20139. https:\/\/doi.org\/10.1007\/s40257-015-0171-3.","journal-title":"Am J Clin Dermatol"},{"key":"1829_CR2","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1007\/s00403-013-1402-1","volume":"306","author":"FC Beikert","year":"2014","unstructured":"Beikert FC, Langenbruch AK, Radtke MA, Kornek T, Purwins S, Augustin M. Willingness to pay and quality of life in patients with atopic dermatitis. Arch Dermatol Res. 2014;306:279\u201386. https:\/\/doi.org\/10.1007\/s00403-013-1402-1.","journal-title":"Arch Dermatol Res"},{"issue":"Suppl 7","key":"1829_CR3","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/jdv.18168","volume":"36","author":"M Augustin","year":"2022","unstructured":"Augustin M, Misery L, von Kobyletzki L, Armario-Hita JC, Mealing S, Redding M. Unveiling the true costs and societal impacts of moderate-to-severe atopic dermatitis in Europe. J Eur Acad Dermatol Venereol. 2022;36(Suppl 7):3\u201316. https:\/\/doi.org\/10.1111\/jdv.18168.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1829_CR4","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1080\/14737167.2019.1549491","volume":"19","author":"M Gutknecht","year":"2019","unstructured":"Gutknecht M, Reinert R, Augustin M. Review of health economic analyses in atopic dermatitis: how diverse is the literature? Expert Rev Pharmacoecon Outcomes Res. 2019;19:127\u201345. https:\/\/doi.org\/10.1080\/14737167.2019.1549491.","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"1829_CR5","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1093\/bjd\/ljae250","volume":"191","author":"K Hagenstr\u00f6m","year":"2024","unstructured":"Hagenstr\u00f6m K, Klinger T, M\u00fcller K, Willers C, Augustin M. Utilization and related harms of systemic glucocorticosteroids for atopic dermatitis: claims data analysis. Br J Dermatol. 2024;191:719\u201327. https:\/\/doi.org\/10.1093\/bjd\/ljae250.","journal-title":"Br J Dermatol"},{"key":"1829_CR6","doi-asserted-by":"publisher","first-page":"158","DOI":"10.18176\/jiaci.0906","volume":"33","author":"JC Armario-Hita","year":"2023","unstructured":"Armario-Hita JC, Gal\u00e1n-Guti\u00e9rrez M, Dodero-Anillo JM, Carrascosa JM, Ruiz-Villaverde R. Updated review on treatment of atopic dermatitis. J Investig Allergol Clin Immunol. 2023;33:158\u201367. https:\/\/doi.org\/10.18176\/jiaci.0906.","journal-title":"J Investig Allergol Clin Immunol"},{"key":"1829_CR7","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1111\/ddg.15230","volume":"22","author":"T Werfel","year":"2024","unstructured":"Werfel T, Heratizadeh A, Aberer W, Augustin M, Biedermann T, Bauer A, et\u00a0al. S3 Guideline atopic dermatitis: part 1\u2014General aspects, topical and non-drug therapies, special patient groups. J Dtsch Dermatol Ges. 2024;22:137\u201353. https:\/\/doi.org\/10.1111\/ddg.15230.","journal-title":"J Dtsch Dermatol Ges"},{"key":"1829_CR8","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1111\/bjd.15928","volume":"178","author":"AM Drucker","year":"2018","unstructured":"Drucker AM, Eyerich K, de Bruin-Weller MS, Thyssen JP, Spuls PI, Irvine AD, et\u00a0al. Use of systemic corticosteroids for atopic dermatitis: International Eczema Council consensus statement. Br J Dermatol. 2018;178:768\u201375. https:\/\/doi.org\/10.1111\/bjd.15928.","journal-title":"Br J Dermatol"},{"key":"1829_CR9","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1111\/j.1610-0387.2008.06967.x","volume":"7","author":"J Schmitt","year":"2009","unstructured":"Schmitt J, Schmitt NM, Kirch W, Meurer M. Outpatient care and medical treatment of children and adults with atopic eczema. J Dtsch Dermatol Ges. 2009;7:345\u201351. https:\/\/doi.org\/10.1111\/j.1610-0387.2008.06967.x.","journal-title":"J Dtsch Dermatol Ges"},{"key":"1829_CR10","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1111\/ddg.12958","volume":"15","author":"J Schmitt","year":"2017","unstructured":"Schmitt J, Abraham S, Trautmann F, Stephan V, F\u00f6lster-Holst R, Homey B, et\u00a0al. Usage and effectiveness of systemic treatments in adults with severe atopic eczema: first results of the German Atopic Eczema Registry TREATgermany. J Dtsch Dermatol Ges. 2017;15:49\u201359. https:\/\/doi.org\/10.1111\/ddg.12958.","journal-title":"J Dtsch Dermatol Ges"},{"key":"1829_CR11","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/j.jaad.2015.10.043","volume":"74","author":"EL Simpson","year":"2016","unstructured":"Simpson EL, Bieber T, Eckert L, Wu R, Ardeleanu M, Graham NMH, et\u00a0al. Patient burden of moderate to severe atopic dermatitis (AD): insights from a phase 2b clinical trial of dupilumab in adults. J Am Acad Dermatol. 2016;74:491\u20138. https:\/\/doi.org\/10.1016\/j.jaad.2015.10.043.","journal-title":"J Am Acad Dermatol"},{"key":"1829_CR12","doi-asserted-by":"publisher","first-page":"593","DOI":"10.2147\/CLEP.S315888","volume":"13","author":"K Hagenstr\u00f6m","year":"2021","unstructured":"Hagenstr\u00f6m K, Sauer K, Mohr N, Dettmann M, Glaeske G, Petersen J, et\u00a0al. Prevalence and medications of atopic dermatitis in Germany: claims data analysis. Clin Epidemiol. 2021;13:593\u2013602. https:\/\/doi.org\/10.2147\/CLEP.S315888.","journal-title":"Clin Epidemiol"},{"key":"1829_CR13","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1007\/s00105-021-04885-3","volume":"72","author":"A Langenbruch","year":"2021","unstructured":"Langenbruch A, Mohr N, Abeck F, Schmitt J, St\u00e4nder S, Werfel T, et\u00a0al. Qualit\u00e4t der dermatologischen Versorgung von Neurodermitis in Deutschland\u2014keine Verbesserung der Indikatoren nach 10\u00a0Jahren. Hautarzt. 2021;72:1079\u201389. https:\/\/doi.org\/10.1007\/s00105-021-04885-3.","journal-title":"Hautarzt"},{"key":"1829_CR14","doi-asserted-by":"publisher","first-page":"adv00830","DOI":"10.2340\/actadv.v102.3932","volume":"102","author":"M Augustin","year":"2022","unstructured":"Augustin M, Costanzo A, Pink A, Seneschal J, Schuster C, Mert C, et\u00a0al. Real-world treatment patterns and treatment benefits among adult patients with atopic dermatitis: results from the atopic dermatitis patient satisfaction and unmet need survey. Acta Derm Venereol. 2022;102:adv00830. https:\/\/doi.org\/10.2340\/actadv.v102.3932.","journal-title":"Acta Derm Venereol"},{"key":"1829_CR15","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1016\/j.jaad.2017.09.074","volume":"78","author":"SH Yu","year":"2018","unstructured":"Yu SH, Drucker AM, Lebwohl M, Silverberg JI. A systematic review of the safety and efficacy of systemic corticosteroids in atopic dermatitis. J Am Acad Dermatol. 2018;78:733\u2013740.e11. https:\/\/doi.org\/10.1016\/j.jaad.2017.09.074.","journal-title":"J Am Acad Dermatol"},{"key":"1829_CR16","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1007\/s10654-019-00500-x","volume":"34","author":"W Hoffmann","year":"2019","unstructured":"Hoffmann W, Latza U, Baumeister SE, Br\u00fcnger M, Buttmann-Schweiger N, Hardt J, et\u00a0al. Guidelines and recommendations for ensuring Good Epidemiological Practice (GEP): a guideline developed by the German Society for Epidemiology. Eur J Epidemiol. 2019;34:301\u201317. https:\/\/doi.org\/10.1007\/s10654-019-00500-x.","journal-title":"Eur J Epidemiol"},{"key":"1829_CR17","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1007\/978-1-4614-9191-0_5","volume-title":"Health care utilization in Germany","author":"E Swart","year":"2014","unstructured":"Swart E. Health care utilization research using secondary data. In: Health care utilization in Germany. New York: Springer; 2014. p. 63\u201386. https:\/\/doi.org\/10.1007\/978-1-4614-9191-0_5."},{"key":"1829_CR18","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1111\/j.2517-6161.1972.tb00899.x","volume":"34","author":"DR Cox","year":"1972","unstructured":"Cox DR. Regression models and life-tables. J R Stat Soc Ser B Stat Methodol. 1972;34:187\u2013202. https:\/\/doi.org\/10.1111\/j.2517-6161.1972.tb00899.x.","journal-title":"J R Stat Soc Ser B Stat Methodol"},{"key":"1829_CR19","doi-asserted-by":"publisher","DOI":"10.1214\/aos\/1176345976","author":"PK Andersen","year":"1982","unstructured":"Andersen PK, Gill RD. Cox\u2019s regression model for counting processes: a large sample study. Ann Stat. 1982. https:\/\/doi.org\/10.1214\/aos\/1176345976.","journal-title":"Ann Stat"},{"key":"1829_CR20","unstructured":"Therneau TM. CRAN: Contributed Packages; 2001."},{"key":"1829_CR21","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1111\/jdv.18345","volume":"36","author":"A Wollenberg","year":"2022","unstructured":"Wollenberg A, Kinberger M, Arents B, Aszodi N, Avila Valle G, Barbarot S, et\u00a0al. European Guideline (EuroGuiDerm) on atopic eczema: part I\u2014Systemic therapy. J Eur Acad Dermatol Venereol. 2022;36:1409\u201331. https:\/\/doi.org\/10.1111\/jdv.18345.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1829_CR22","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1517\/14740338.2016.1140743","volume":"15","author":"M Oray","year":"2016","unstructured":"Oray M, Abu Samra K, Ebrahimiadib N, Meese H, Foster CS. Long-term side effects of glucocorticoids. Expert Opin Drug Saf. 2016;15:457\u201365. https:\/\/doi.org\/10.1517\/14740338.2016.1140743.","journal-title":"Expert Opin Drug Saf"},{"key":"1829_CR23","doi-asserted-by":"publisher","first-page":"263","DOI":"10.11005\/jbm.2014.21.4.263","volume":"21","author":"S-R Kim","year":"2014","unstructured":"Kim S-R, Park Y-G, Kang SY, Nam KW, Park Y-G, Ha Y-C. Undertreatment of osteoporosis following hip fractures in Jeju cohort study. J Bone Metab. 2014;21:263\u20138. https:\/\/doi.org\/10.11005\/jbm.2014.21.4.263.","journal-title":"J Bone Metab"},{"key":"1829_CR24","doi-asserted-by":"publisher","first-page":"2547","DOI":"10.1056\/NEJMcp1800214","volume":"379","author":"L Buckley","year":"2018","unstructured":"Buckley L, Humphrey MB. Glucocorticoid-induced osteoporosis. N Engl J Med. 2018;379:2547\u201356. https:\/\/doi.org\/10.1056\/NEJMcp1800214.","journal-title":"N Engl J Med"},{"key":"1829_CR25","doi-asserted-by":"publisher","first-page":"e004587","DOI":"10.1136\/bmjopen-2013-004587","volume":"4","author":"S Narum","year":"2014","unstructured":"Narum S, Westergren T, Klemp M. Corticosteroids and risk of gastrointestinal bleeding: a systematic review and meta-analysis. BMJ Open. 2014;4:e004587. https:\/\/doi.org\/10.1136\/bmjopen-2013-004587.","journal-title":"BMJ Open"},{"key":"1829_CR26","doi-asserted-by":"publisher","first-page":"1187100","DOI":"10.3389\/fcvm.2023.1187100","volume":"10","author":"H-W Deng","year":"2023","unstructured":"Deng H-W, Mei W-Y, Xu Q, Zhai Y-S, Lin X-X, Li J, et\u00a0al. The role of glucocorticoids in increasing cardiovascular risk. Front Cardiovasc Med. 2023;10:1187100. https:\/\/doi.org\/10.3389\/fcvm.2023.1187100.","journal-title":"Front Cardiovasc Med"},{"key":"1829_CR27","doi-asserted-by":"publisher","first-page":"4645","DOI":"10.1210\/jc.2009-1412","volume":"94","author":"MS Cooper","year":"2009","unstructured":"Cooper MS, Stewart PM. 11Beta-hydroxysteroid dehydrogenase type 1 and its role in the hypothalamus\u2013pituitary\u2013adrenal axis, metabolic syndrome, and inflammation. J Clin Endocrinol Metab. 2009;94:4645\u201354. https:\/\/doi.org\/10.1210\/jc.2009-1412.","journal-title":"J Clin Endocrinol Metab"},{"key":"1829_CR28","doi-asserted-by":"publisher","first-page":"100255","DOI":"10.1016\/j.ynstr.2020.100255","volume":"13","author":"VAD Holanda","year":"2020","unstructured":"Holanda VAD, Oliveira MC, Da Silva Junior ED, Calo\u2019 G, Ruzza C, Gavioli EC. Blockade of nociceptin\/orphanin FQ signaling facilitates an active copying strategy due to acute and repeated stressful stimuli in mice. Neurobiol Stress. 2020;13:100255. https:\/\/doi.org\/10.1016\/j.ynstr.2020.100255.","journal-title":"Neurobiol Stress"},{"key":"1829_CR29","doi-asserted-by":"publisher","first-page":"908727","DOI":"10.3389\/fendo.2022.908727","volume":"13","author":"MR Laurent","year":"2022","unstructured":"Laurent MR, Goemaere S, Verroken C, Bergmann P, Body J-J, Bruy\u00e8re O, et\u00a0al. Prevention and treatment of glucocorticoid-induced osteoporosis in adults: consensus recommendations from the Belgian Bone Club. Front Endocrinol (Lausanne). 2022;13:908727. https:\/\/doi.org\/10.3389\/fendo.2022.908727.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"1829_CR30","doi-asserted-by":"publisher","first-page":"771096","DOI":"10.3389\/fcvm.2022.771096","volume":"9","author":"M Kantauskaite","year":"2022","unstructured":"Kantauskaite M, Bolten K, Boschheidgen M, Schmidt C, Kolb T, Eckardt KU, et\u00a0al. Serum calcification propensity and calcification of the abdominal aorta in patients with primary aldosteronism. Front Cardiovasc Med. 2022;9:771096. https:\/\/doi.org\/10.3389\/fcvm.2022.771096.","journal-title":"Front Cardiovasc Med"},{"key":"1829_CR31","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1136\/ard-2023-224185","volume":"82","author":"H So","year":"2023","unstructured":"So H, Lam TO, Meng H, Lam SHM, Tam L-S. Time and dose-dependent effect of systemic glucocorticoids on major adverse cardiovascular event in patients with rheumatoid arthritis: a population-based study. Ann Rheum Dis. 2023;82:1387\u201393. https:\/\/doi.org\/10.1136\/ard-2023-224185.","journal-title":"Ann Rheum Dis"},{"key":"1829_CR32","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1159\/000365892","volume":"65","author":"X Liu","year":"2014","unstructured":"Liu X, Zhu X, Miao Q, Ye H, Zhang Z, Li Y-M. Hyperglycemia induced by glucocorticoids in nondiabetic patients: a meta-analysis. Ann Nutr Metab. 2014;65:324\u201332. https:\/\/doi.org\/10.1159\/000365892.","journal-title":"Ann Nutr Metab"},{"key":"1829_CR33","doi-asserted-by":"publisher","first-page":"180","DOI":"10.3803\/EnM.2017.32.2.180","volume":"32","author":"S Suh","year":"2017","unstructured":"Suh S, Park MK. Glucocorticoid-Induced diabetes mellitus: an important but overlooked problem. Endocrinol Metab (Seoul). 2017;32:180\u20139. https:\/\/doi.org\/10.3803\/EnM.2017.32.2.180.","journal-title":"Endocrinol Metab (Seoul)"},{"key":"1829_CR34","doi-asserted-by":"publisher","first-page":"2222","DOI":"10.1111\/dom.14808","volume":"24","author":"P Ambery","year":"2022","unstructured":"Ambery P, Adamsson Eryd S, Jenkins-Jones S, Heywood B, Berni E, Brown MN, et\u00a0al. The absolute risk of incident type 2 diabetes following exposure to systemic corticosteroids in selected steroid-related and phenotypic groups. Diabetes Obes Metab. 2022;24:2222\u201331. https:\/\/doi.org\/10.1111\/dom.14808.","journal-title":"Diabetes Obes Metab"},{"key":"1829_CR35","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.2025.128","author":"T Lagerberg","year":"2025","unstructured":"Lagerberg T, Gustafsson TT, Molero Y, Forton J, Sariaslan A, Chang Z, et\u00a0al. Oral glucocorticoids and risk of psychiatric and suicidal behaviour outcomes: population-based cohort study. Br J Psychiatry. 2025. https:\/\/doi.org\/10.1192\/bjp.2025.128.","journal-title":"Br J Psychiatry"},{"key":"1829_CR36","doi-asserted-by":"publisher","first-page":"e1442","DOI":"10.1210\/clinem\/dgad701","volume":"109","author":"A-SCAM Koning","year":"2024","unstructured":"Koning A-SCAM, van der Meulen M, Schaap D, Satoer DD, Vinkers CH, van Rossum EFC, et\u00a0al. Neuropsychiatric adverse effects of synthetic glucocorticoids: a systematic review and meta-analysis. J Clin Endocrinol Metab. 2024;109:e1442\u201351. https:\/\/doi.org\/10.1210\/clinem\/dgad701.","journal-title":"J Clin Endocrinol Metab"},{"key":"1829_CR37","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1111\/cea.70125","volume":"55","author":"Y Kim","year":"2025","unstructured":"Kim Y, Seo G, Koopman JJE, Yee J. Real-world effectiveness and safety of JAK inhibitors in atopic dermatitis: a systematic review and meta-analysis. Clin Exp Allergy. 2025;55:755\u201372. https:\/\/doi.org\/10.1111\/cea.70125.","journal-title":"Clin Exp Allergy"},{"key":"1829_CR38","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1111\/1346-8138.70138","volume":"53","author":"M Shiba","year":"2026","unstructured":"Shiba M, Hagino T, Uchiyama A, Saeki H, Fujimoto E, Motegi S-I, et\u00a0al. Long-term, site-specific effectiveness of tralokinumab in atopic dermatitis: a 72-week real-world study. J Dermatol. 2026;53:454\u201360. https:\/\/doi.org\/10.1111\/1346-8138.70138.","journal-title":"J Dermatol"},{"issue":"1","key":"1829_CR39","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/j.jaad.2025.09.034","volume":"94","author":"T Hagino","year":"2026","unstructured":"Hagino T, Uchiyama A, Kosaka K, Araki T, Saeki H, Fujimoto E, et\u00a0al. A 48-week real-world outcome of tralokinumab treatment for atopic dermatitis: systemic therapy-na\u00efve versus systemic therapy-experienced patients. J Am Acad Dermatol. 2026;94(1):321\u20132. https:\/\/doi.org\/10.1016\/j.jaad.2025.09.034 (Epub 2025 Sep 15).","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"1829_CR40","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1016\/j.jaad.2025.01.052","volume":"92","author":"T Hagino","year":"2025","unstructured":"Hagino T, Saeki H, Fujimoto E, Kanda N. A 96-week real-world outcome of upadacitinib treatment for atopic dermatitis: systemic therapy-naive versus -experienced patients. J Am Acad Dermatol. 2025;92(5):1049\u201355. https:\/\/doi.org\/10.1016\/j.jaad.2025.01.052 (Epub 2025 Jan 27).","journal-title":"J Am Acad Dermatol"},{"key":"1829_CR41","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1093\/oxfordjournals.aje.a114019","volume":"121","author":"RD Abbott","year":"1985","unstructured":"Abbott RD. Logistic regression in survival analysis. Am J Epidemiol. 1985;121:465\u201371. https:\/\/doi.org\/10.1093\/oxfordjournals.aje.a114019.","journal-title":"Am J Epidemiol"},{"key":"1829_CR42","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1016\/0021-9681(83)90165-0","volume":"36","author":"MS Green","year":"1983","unstructured":"Green MS, Symons MJ. A comparison of the logistic risk function and the proportional hazards model in prospective epidemiologic studies. J Chronic Dis. 1983;36:715\u201323. https:\/\/doi.org\/10.1016\/0021-9681(83)90165-0.","journal-title":"J Chronic Dis"},{"key":"1829_CR43","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1093\/oxfordjournals.aje.a113883","volume":"120","author":"DJ Gordon","year":"1984","unstructured":"Gordon DJ, Probstfield JL, Rubenstein C, Bremner WF, Leon AS, Karon JM, et\u00a0al. Coronary risk factors and exercise test performance in asymptomatic hypercholesterolemic men: application of proportional hazards analysis. Am J Epidemiol. 1984;120:210\u201324. https:\/\/doi.org\/10.1093\/oxfordjournals.aje.a113883.","journal-title":"Am J Epidemiol"},{"key":"1829_CR44","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1111\/jdv.13813","volume":"31","author":"MA Radtke","year":"2017","unstructured":"Radtke MA, Sch\u00e4fer I, Glaeske G, Jacobi A, Augustin M. Prevalence and comorbidities in adults with psoriasis compared to atopic eczema. J Eur Acad Dermatol Venereol. 2017;31:151\u20137. https:\/\/doi.org\/10.1111\/jdv.13813.","journal-title":"J Eur Acad Dermatol Venereol"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-026-01829-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-026-01829-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-026-01829-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T16:29:48Z","timestamp":1787243388000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-026-01829-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,22]]},"references-count":44,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["1829"],"URL":"https:\/\/doi.org\/10.1007\/s13555-026-01829-4","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,22]]},"assertion":[{"value":"2 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Katharina M\u00fcller,\u00a0Dr. Ricarda Graf, Dr. Kristina Hagenstr\u00f6m\u00a0and Theresa Klinger declare no conflicts of interest. Prof. Dr.\u00a0Matthias Augustin has served as a consultant, lecturer, researcher, and\/or has received institutional research grants from companies manufacturing drugs for atopic dermatitis, including AbbVie, Almirall, Beiersdorf, Eli Lilly, Galderma, LEO, Novartis, Pfizer, and Sanofi-Genzyme.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was conducted using anonymized statutory health insurance claims data from DAK-G. Permission to access and use the data for the present study was granted by DAK-G as the data holder. As the analyses were based exclusively on anonymized claims data, informed consent was not required. The study was conducted in accordance with national guidelines for the use of administrative databases [\n                      \n                      ,\n                      \n                      ]. According to these guidelines, ethics committee approval was not required.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}